Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Status:
Completed
Trial end date:
2018-03-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for
intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2
mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to
age-related macular degeneration (AMD) in the study eye.